These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 3288717)

  • 1. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.
    Factor SA; Sanchez-Ramos JR; Weiner WJ
    J Neurol Neurosurg Psychiatry; 1988 Apr; 51(4):529-33. PubMed ID: 3288717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
    Pezzoli G; Martignoni E; Pacchetti C; Angeleri VA; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
    Mov Disord; 1994 Jul; 9(4):431-6. PubMed ID: 7969210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease.
    Pezzoli G; Martignoni E; Pacchetti C; Angeleri V; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
    Neurology; 1995 Mar; 45(3 Suppl 3):S22-7. PubMed ID: 7715793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic malignant-like syndrome after rapid switch from bromocriptine to pergolide.
    Reimer J; Kuhlmann A; Müller T
    Parkinsonism Relat Disord; 2002 Dec; 9(2):115-6. PubMed ID: 12473402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.
    Lamberts SW; Quik RF
    J Clin Endocrinol Metab; 1991 Mar; 72(3):635-41. PubMed ID: 1997518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonists in the treatment of Parkinson's disease.
    Pahwa R; Koller WC
    Cleve Clin J Med; 1995; 62(4):212-7. PubMed ID: 7641388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
    Goetz CG; Tanner CM; Glantz RH; Klawans HL
    Neurology; 1985 May; 35(5):749-51. PubMed ID: 3990974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease.
    Clarke C E; Speller J M
    Cochrane Database Syst Rev; 2000; (2):CD000236. PubMed ID: 10796705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients.
    Kuno S; Mizuta E; Yamasaki S; Araki I
    Parkinsonism Relat Disord; 2004 Mar; 10(3):181-7. PubMed ID: 15036175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pergolide in the treatment of Parkinson's disease.
    Mizuno Y; Kondo T; Narabayashi H
    Neurology; 1995 Mar; 45(3 Suppl 3):S13-21. PubMed ID: 7715792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S79-82. PubMed ID: 12211145
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.
    Davey P; Rajan N; Lees M; Aristides M
    Value Health; 2001; 4(4):308-15. PubMed ID: 11705298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
    Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic agonists in the treatment of Parkinson's disease.
    Goetz CG
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 50-4; discussion 54-7. PubMed ID: 1977104
    [No Abstract]   [Full Text] [Related]  

  • 17. Sleep attacks and Parkinson's disease treatment.
    Ferreira JJ; Galitzky M; Montastruc JL; Rascol O
    Lancet; 2000 Apr; 355(9212):1333-4. PubMed ID: 10776750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agonist substitution in advanced Parkinson's disease.
    Goetz CG; Shannon KM; Tanner CM; Carroll VS; Klawans HL
    Neurology; 1989 Aug; 39(8):1121-2. PubMed ID: 2761708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
    Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M
    Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pergolide and bromocriptine therapy in parkinsonism.
    LeWitt PA; Ward CD; Larsen TA; Raphaelson MI; Newman RP; Foster N; Dambrosia JM; Calne DB
    Neurology; 1983 Aug; 33(8):1009-14. PubMed ID: 6348585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.